Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.13
CRL's Cash-to-Debt is ranked lower than
90% of the 244 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.13 vs. CRL: 0.13 )
Ranked among companies with meaningful Cash-to-Debt only.
CRL' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04  Med: 0.29 Max: 15.68
Current: 0.13
0.04
15.68
Equity-to-Asset 0.36
CRL's Equity-to-Asset is ranked lower than
81% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. CRL: 0.36 )
Ranked among companies with meaningful Equity-to-Asset only.
CRL' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.28  Med: 0.48 Max: 0.72
Current: 0.36
-0.28
0.72
Debt-to-Equity 1.16
CRL's Debt-to-Equity is ranked lower than
87% of the 150 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.35 vs. CRL: 1.16 )
Ranked among companies with meaningful Debt-to-Equity only.
CRL' s Debt-to-Equity Range Over the Past 10 Years
Min: -3.68  Med: 0.57 Max: 1.8
Current: 1.16
-3.68
1.8
Debt-to-EBITDA 2.60
CRL's Debt-to-EBITDA is ranked lower than
61% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.62 vs. CRL: 2.60 )
Ranked among companies with meaningful Debt-to-EBITDA only.
CRL' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.42  Med: 2.65 Max: 3.27
Current: 2.6
-3.42
3.27
Interest Coverage 9.94
CRL's Interest Coverage is ranked lower than
66% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.25 vs. CRL: 9.94 )
Ranked among companies with meaningful Interest Coverage only.
CRL' s Interest Coverage Range Over the Past 10 Years
Min: 4.09  Med: 8.2 Max: 14.87
Current: 9.94
4.09
14.87
Piotroski F-Score: 6
Altman Z-Score: 2.89
Beneish M-Score: -2.51
WACC vs ROIC
6.87%
10.19%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 15.92
CRL's Operating Margin % is ranked higher than
84% of the 229 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. CRL: 15.92 )
Ranked among companies with meaningful Operating Margin % only.
CRL' s Operating Margin % Range Over the Past 10 Years
Min: -33.48  Med: 14.3 Max: 18.46
Current: 15.92
-33.48
18.46
Net Margin % 10.72
CRL's Net Margin % is ranked higher than
81% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.44 vs. CRL: 10.72 )
Ranked among companies with meaningful Net Margin % only.
CRL' s Net Margin % Range Over the Past 10 Years
Min: -38.84  Med: 9.4 Max: 12.55
Current: 10.72
-38.84
12.55
ROE % 21.67
CRL's ROE % is ranked higher than
89% of the 222 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.01 vs. CRL: 21.67 )
Ranked among companies with meaningful ROE % only.
CRL' s ROE % Range Over the Past 10 Years
Min: -34.11  Med: 16.92 Max: 21.67
Current: 21.67
-34.11
21.67
ROA % 7.20
CRL's ROA % is ranked higher than
77% of the 244 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.54 vs. CRL: 7.20 )
Ranked among companies with meaningful ROA % only.
CRL' s ROA % Range Over the Past 10 Years
Min: -21.02  Med: 6.29 Max: 7.58
Current: 7.2
-21.02
7.58
ROC (Joel Greenblatt) % 33.93
CRL's ROC (Joel Greenblatt) % is ranked higher than
76% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.64 vs. CRL: 33.93 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CRL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -50.32  Med: 19.05 Max: 33.93
Current: 33.93
-50.32
33.93
3-Year Revenue Growth Rate 13.40
CRL's 3-Year Revenue Growth Rate is ranked higher than
72% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.10 vs. CRL: 13.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CRL' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -17.6  Med: 7 Max: 13.4
Current: 13.4
-17.6
13.4
3-Year EBITDA Growth Rate 14.20
CRL's 3-Year EBITDA Growth Rate is ranked higher than
65% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.90 vs. CRL: 14.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CRL' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -18.2  Med: 8.15 Max: 25.2
Current: 14.2
-18.2
25.2
3-Year EPS without NRI Growth Rate 14.40
CRL's 3-Year EPS without NRI Growth Rate is ranked higher than
66% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. CRL: 14.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CRL' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -29.4  Med: 9.35 Max: 43.3
Current: 14.4
-29.4
43.3
GuruFocus has detected 2 Warning Signs with Charles River Laboratories International Inc CRL.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CRL's 30-Y Financials

Financials (Next Earnings Date: 2018-02-14)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

CRL Guru Trades in Q4 2016

Joel Greenblatt 2,750 sh (New)
Robert Olstein 136,035 sh (+58.87%)
Jim Simons 1,120,209 sh (+19.69%)
John Rogers 1,576,856 sh (+10.51%)
Ken Fisher 490,104 sh (-3.65%)
PRIMECAP Management 875,000 sh (-3.81%)
Paul Tudor Jones 8,520 sh (-4.27%)
Pioneer Investments 164,423 sh (-44.77%)
» More
Q1 2017

CRL Guru Trades in Q1 2017

Jeremy Grantham 2,500 sh (New)
Joel Greenblatt 116,298 sh (+4129.02%)
Paul Tudor Jones 11,224 sh (+31.74%)
John Rogers 2,060,420 sh (+30.67%)
PRIMECAP Management 874,000 sh (-0.11%)
Pioneer Investments 163,725 sh (-0.42%)
Jim Simons 1,066,509 sh (-4.79%)
Ken Fisher 463,712 sh (-5.38%)
Robert Olstein 108,055 sh (-20.57%)
» More
Q2 2017

CRL Guru Trades in Q2 2017

Ray Dalio 6,709 sh (New)
Jeremy Grantham 3,200 sh (+28.00%)
Jim Simons 1,219,883 sh (+14.38%)
Ken Fisher 457,572 sh (-1.32%)
John Rogers 1,950,367 sh (-5.34%)
Robert Olstein 77,135 sh (-28.62%)
Pioneer Investments 99,110 sh (-39.47%)
Paul Tudor Jones 6,310 sh (-43.78%)
PRIMECAP Management 453,000 sh (-48.17%)
Joel Greenblatt 2,299 sh (-98.02%)
» More
Q3 2017

CRL Guru Trades in Q3 2017

Joel Greenblatt 45,906 sh (+1896.78%)
Pioneer Investments 131,661 sh (+32.84%)
Jim Simons 1,339,709 sh (+9.82%)
Jeremy Grantham 3,200 sh (unchged)
Paul Tudor Jones Sold Out
Ken Fisher 452,156 sh (-1.18%)
PRIMECAP Management 426,200 sh (-5.92%)
John Rogers 1,680,066 sh (-13.86%)
Robert Olstein 60,112 sh (-22.07%)
Ray Dalio 2,574 sh (-61.63%)
» More
» Details

Insider Trades

Latest Guru Trades with CRL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Rogers 2017-09-30 Reduce -13.86%0.32%$96.72 - $109.26 $ 102.29-0%1,680,066
Ken Fisher 2017-09-30 Reduce -1.18%$96.72 - $109.26 $ 102.29-0%452,156
Robert Olstein 2017-09-30 Reduce -22.07%0.22%$96.72 - $109.26 $ 102.29-0%60,112
Joel Greenblatt 2017-09-30 Add 1896.78%0.07%$96.72 - $109.26 $ 102.29-0%45,906
John Rogers 2017-06-30 Reduce -5.34%0.12%$87.09 - $101.54 $ 102.2911%1,950,367
Ken Fisher 2017-06-30 Reduce -1.32%$87.09 - $101.54 $ 102.2911%457,572
Robert Olstein 2017-06-30 Reduce -28.62%0.35%$87.09 - $101.54 $ 102.2911%77,135
Joel Greenblatt 2017-06-30 Reduce -98.02%0.13%$87.09 - $101.54 $ 102.2911%2,299
John Rogers 2017-03-31 Add 30.67%0.51%$76.53 - $91.4 $ 102.2920%2,060,420
Ken Fisher 2017-03-31 Reduce -5.38%$76.53 - $91.4 $ 102.2920%463,712
Joel Greenblatt 2017-03-31 Add 4129.02%0.13%$76.53 - $91.4 $ 102.2920%116,298
Robert Olstein 2017-03-31 Reduce -20.57%0.28%$76.53 - $91.4 $ 102.2920%108,055
John Rogers 2016-12-31 Add 10.51%0.14%$67.4 - $83.68 $ 102.2935%1,576,856
Ken Fisher 2016-12-31 Reduce -3.65%$67.4 - $83.68 $ 102.2935%490,104
Robert Olstein 2016-12-31 Add 58.87%0.5%$67.4 - $83.68 $ 102.2935%136,035
Joel Greenblatt 2016-12-31 New Buy$67.4 - $83.68 $ 102.2935%2,750
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 541711    SIC: 8732
Compare:NAS:PRAH, NAS:INCR, NAS:EXAS, MIL:DIA, NAS:BRKR, XTER:AFX, XTER:SRT3, NAS:ICLR, NYSE:BIO, NAS:PRXL, NYSE:ALR, NAS:VWR, NAS:DXCM, NAS:QGEN, SHSE:603658, NYSE:PKI, NAS:NEOG, BSP:FLRY3, TSE:4544, BSP:DASA3 » details
Traded in other countries:RV6.Germany,
Headquarter Location:USA
Charles River Laboratories International Inc is a pharmaceutical company providing drug discovery and development services. The company provides animal models for laboratory testing, and offers manufacturing testing services to various industries.

Charles River Laboratories is a leading provider of drug discovery and development services. With roughly 50% of market share worldwide, the research model and services segment is the leading provider of animal models for laboratory testing. The remainder of Charles River's revenue comes from its preclinical services segment, which offers discovery, toxicology, pathology, and its manufacturing testing services to pharmaceutical, biotechnology, and device companies.

Guru Investment Theses on Charles River Laboratories International Inc

John Rogers Comments on Charles River Laboratories Intl - Jan 20, 2017

Other holdings underperformed. Scientific research firm Charles River Laboratories Intl, Inc. (NYSE:CRL) slid –8.58% due to contracting customer spending and a general downturn in health care stocks. Like other similar firms, Charles River expanded over the last 15 years to be able to handle peak medical research, but as drug companies scaled back, there was clearly overcapacity. The company’s drug discovery business is still a bit slack. That said, many health care stocks slid this quarter during a huge rotation to financials. We think the current issues are largely cyclical but the secular push toward solving medical problems through pharmaceuticals remains intact—a long-term tailwind for Charles River.



From John Rogers (Trades, Portfolio)' Ariel Fund fourth quarter 2016 commentary.



Check out John Rogers latest stock trades

Top Ranked Articles about Charles River Laboratories International Inc

John Rogers Buys Cardinal Health, Mattel, Nielsen Guru's largest 1st-quarter buys
John Rogers (Trades, Portfolio) is the founder of Ariel Investment LLC, which he started in 1983. He manages a portfolio composed of 188 stocks with a total value of $8.505 billion. During the first quarter the guru bought shares in the following stocks: Read more...
John Rogers Comments on Charles River Laboratories Intl Guru stock highlight
Other holdings underperformed. Scientific research firm Charles River Laboratories Intl, Inc. (NYSE:CRL) slid –8.58% due to contracting customer spending and a general downturn in health care stocks. Like other similar firms, Charles River expanded over the last 15 years to be able to handle peak medical research, but as drug companies scaled back, there was clearly overcapacity. The company’s drug discovery business is still a bit slack. That said, many health care stocks slid this quarter during a huge rotation to financials. We think the current issues are largely cyclical but the secular push toward solving medical problems through pharmaceuticals remains intact—a long-term tailwind for Charles River. Read more...

Ratios

vs
industry
vs
history
PE Ratio 24.97
CRL's PE Ratio is ranked higher than
66% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 34.50 vs. CRL: 24.97 )
Ranked among companies with meaningful PE Ratio only.
CRL' s PE Ratio Range Over the Past 10 Years
Min: 8.58  Med: 24.83 Max: 95.66
Current: 24.97
8.58
95.66
Forward PE Ratio 18.48
CRL's Forward PE Ratio is ranked higher than
73% of the 33 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.26 vs. CRL: 18.48 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 24.90
CRL's PE Ratio without NRI is ranked higher than
67% of the 108 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.88 vs. CRL: 24.90 )
Ranked among companies with meaningful PE Ratio without NRI only.
CRL' s PE Ratio without NRI Range Over the Past 10 Years
Min: 8.51  Med: 24.56 Max: 77.86
Current: 24.9
8.51
77.86
Price-to-Owner-Earnings 22.87
CRL's Price-to-Owner-Earnings is ranked higher than
70% of the 73 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 34.21 vs. CRL: 22.87 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
CRL' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 10.56  Med: 22.8 Max: 323.25
Current: 22.87
10.56
323.25
PB Ratio 4.75
CRL's PB Ratio is ranked lower than
61% of the 223 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.97 vs. CRL: 4.75 )
Ranked among companies with meaningful PB Ratio only.
CRL' s PB Ratio Range Over the Past 10 Years
Min: 0.75  Med: 3.17 Max: 6.01
Current: 4.75
0.75
6.01
PS Ratio 2.68
CRL's PS Ratio is ranked higher than
61% of the 217 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.68 vs. CRL: 2.68 )
Ranked among companies with meaningful PS Ratio only.
CRL' s PS Ratio Range Over the Past 10 Years
Min: 1.12  Med: 2.22 Max: 3.83
Current: 2.68
1.12
3.83
Price-to-Free-Cash-Flow 22.89
CRL's Price-to-Free-Cash-Flow is ranked higher than
64% of the 74 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 24.99 vs. CRL: 22.89 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CRL' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.49  Med: 16.62 Max: 1041.48
Current: 22.89
8.49
1041.48
Price-to-Operating-Cash-Flow 16.68
CRL's Price-to-Operating-Cash-Flow is ranked higher than
64% of the 92 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.00 vs. CRL: 16.68 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CRL' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.82  Med: 12.44 Max: 19.72
Current: 16.68
4.82
19.72
EV-to-EBIT 18.28
CRL's EV-to-EBIT is ranked higher than
67% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.52 vs. CRL: 18.28 )
Ranked among companies with meaningful EV-to-EBIT only.
CRL' s EV-to-EBIT Range Over the Past 10 Years
Min: -10.7  Med: 18 Max: 27.8
Current: 18.28
-10.7
27.8
EV-to-EBITDA 12.92
CRL's EV-to-EBITDA is ranked higher than
69% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.06 vs. CRL: 12.92 )
Ranked among companies with meaningful EV-to-EBITDA only.
CRL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -16.5  Med: 12.1 Max: 16.8
Current: 12.92
-16.5
16.8
EV-to-Revenue 3.18
CRL's EV-to-Revenue is ranked higher than
57% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.94 vs. CRL: 3.18 )
Ranked among companies with meaningful EV-to-Revenue only.
CRL' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.4  Med: 2.7 Max: 4.1
Current: 3.18
1.4
4.1
PEG Ratio 2.71
CRL's PEG Ratio is ranked lower than
54% of the 46 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.98 vs. CRL: 2.71 )
Ranked among companies with meaningful PEG Ratio only.
CRL' s PEG Ratio Range Over the Past 10 Years
Min: 1.01  Med: 2.46 Max: 3.23
Current: 2.71
1.01
3.23
Shiller PE Ratio 156.51
CRL's Shiller PE Ratio is ranked lower than
97% of the 35 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 49.53 vs. CRL: 156.51 )
Ranked among companies with meaningful Shiller PE Ratio only.
CRL' s Shiller PE Ratio Range Over the Past 10 Years
Min: 91.59  Med: 160.62 Max: 1940.5
Current: 156.51
91.59
1940.5
Current Ratio 1.88
CRL's Current Ratio is ranked lower than
67% of the 234 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.51 vs. CRL: 1.88 )
Ranked among companies with meaningful Current Ratio only.
CRL' s Current Ratio Range Over the Past 10 Years
Min: 1.21  Med: 1.98 Max: 3.49
Current: 1.88
1.21
3.49
Quick Ratio 1.62
CRL's Quick Ratio is ranked lower than
66% of the 234 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. CRL: 1.62 )
Ranked among companies with meaningful Quick Ratio only.
CRL' s Quick Ratio Range Over the Past 10 Years
Min: 0.95  Med: 1.66 Max: 3.02
Current: 1.62
0.95
3.02
Days Inventory 32.63
CRL's Days Inventory is ranked higher than
72% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.37 vs. CRL: 32.63 )
Ranked among companies with meaningful Days Inventory only.
CRL' s Days Inventory Range Over the Past 10 Years
Min: 32.63  Med: 41.32 Max: 49.49
Current: 32.63
32.63
49.49
Days Sales Outstanding 63.57
CRL's Days Sales Outstanding is ranked higher than
56% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.49 vs. CRL: 63.57 )
Ranked among companies with meaningful Days Sales Outstanding only.
CRL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 53.42  Med: 59.61 Max: 65.6
Current: 63.57
53.42
65.6
Days Payable 21.37
CRL's Days Payable is ranked lower than
87% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.34 vs. CRL: 21.37 )
Ranked among companies with meaningful Days Payable only.
CRL' s Days Payable Range Over the Past 10 Years
Min: 14.93  Med: 15.77 Max: 24.16
Current: 21.37
14.93
24.16

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 0.10
CRL's 3-Year Average Share Buyback Ratio is ranked higher than
88% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.50 vs. CRL: 0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CRL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -62.6  Med: 0.3 Max: 10.3
Current: 0.1
-62.6
10.3

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.37
CRL's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
73% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.00 vs. CRL: 1.37 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
CRL' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.94  Med: 1.35 Max: 1.78
Current: 1.37
0.94
1.78
Price-to-Median-PS-Value 1.21
CRL's Price-to-Median-PS-Value is ranked lower than
65% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. CRL: 1.21 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CRL' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.55  Med: 1.2 Max: 1.85
Current: 1.21
0.55
1.85
Price-to-Peter-Lynch-Fair-Value 1.92
CRL's Price-to-Peter-Lynch-Fair-Value is ranked lower than
55% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.32 vs. CRL: 1.92 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
CRL' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 1.25  Med: 2.4 Max: 2.78
Current: 1.92
1.25
2.78
Earnings Yield (Greenblatt) % 5.47
CRL's Earnings Yield (Greenblatt) % is ranked higher than
85% of the 246 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.72 vs. CRL: 5.47 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CRL' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -24.3  Med: 5.2 Max: 14.1
Current: 5.47
-24.3
14.1
Forward Rate of Return (Yacktman) % 17.20
CRL's Forward Rate of Return (Yacktman) % is ranked higher than
74% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.99 vs. CRL: 17.20 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
CRL' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 2.8  Med: 5.6 Max: 17.2
Current: 17.2
2.8
17.2

More Statistics

Revenue (TTM) (Mil) $1,845.91
EPS (TTM) $ 4.10
Beta0.93
Short Percentage of Float2.64%
52-Week Range $69.51 - 119.05
Shares Outstanding (Mil)47.36

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 1,846 1,965 2,130 2,286
EPS ($) 5.02 5.51 5.90 6.30
EPS without NRI ($) 5.02 5.51 5.90 6.30
EPS Growth Rate
(Future 3Y To 5Y Estimate)
9.74%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}